Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takesada Mori is active.

Publication


Featured researches published by Takesada Mori.


Biochemical and Biophysical Research Communications | 1988

Synthesis of a new cell penetrating calpain inhibitor (calpeptin)

Toshimasa Tsujinaka; Yuki Kajiwara; Jun-ichi Kambayashi; Masato Sakon; Naoki Higuchi; Takaharu Tanaka; Takesada Mori

N-terminal of Leu-norleucinal or Leu-methioninal was modified to obtain a cell penetrative peptide inhibitor against calpain. Benzyloxycarbonyl (Z) derivatives had less active against papain than phenylbutyryl derivatives and leupeptin. Z-Leu-nLeu-H (calpeptin) was more sensitive to calpain I than Z-Leu-Met-H and leupeptin. Calpeptin was most potent among synthesized inhibitors in terms of preventing the Ca2+-ionophore induced degradation of actin binding protein and P235 in intact platelets. After 30 min incubation with intact platelets, calpeptin completely abolished calpain activity in platelets but no effect was observed in case of leupeptin. Calpeptin also inhibited 20K phosphorylation in platelets stimulated by thrombin, ionomycin or collagen. Thus calpeptin was found to be a useful cell-penetrative calpain inhibitor.


Cancer | 1990

Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers

Hitoshi Shiozaki; Hideaki Tahara; Kenji Kobayashi; Hiroshi Yano; Shigeyuki Tamura; Haruhiko Imamoto; Tokiharu Yano; Kunihiko Oku; Mikiyo Miyata; Kinji Nishiyama; Kazuko Kubo; Takesada Mori

The poor prognosis for esophageal cancer could be improved if lesions were detected at an early stage. To detect early esophageal cancer, endoscopic screening of the esophagus with the Lugol dye method was performed in patients with head and neck cancers who were asymptomatic but regarded as being at high risk for synchronous or metachronous esophageal cancer. of 178 patients screened, 9 had esophageal cancer (5.1%). Eight of these patients (89%) were at early stages with no lymph node metastasis. Most of the lesions (9 of 13 lesions) were not detectable by barium studies or ordinary endoscopic study. the epidemiologic statistical analysis of the patients confirmed that they had a significantly high observed and expected number (O/E) ratio (39.7; P < 0.001). These results demonstrate the value of endoscopic screening of the esophagus with the Lugol dye method in patients with head and neck cancers and imply that endoscopic screening with the Lugol dye method may be useful for detecting early esophageal cancer in individuals at risk for other causes.


Virchows Archiv | 1992

Immunohistochemical evaluation of E-cadherin adhesion molecule expression in human gastric cancer.

Hiroshi Oka; Hitoshi Shiozaki; Kenji Kobayashi; Hideaki Tahara; Shigeyuki Tamura; Mikio Miyata; Doki Y; Keisuke Iihara; Norihisa Matsuyoshi; Shinji Hirano; Masatoshi Takeichi; Takesada Mori

E-cadherin (ECD) is one of subclasses of the cadherin family which plays a major role in the maintenance of intercellular adhesion in epithelial tissues. An immunohistochemical study of ECD expression was performed on gastric adenocarcinoma from 103 patients using our monoclonal antibody for human ECD (HECD-1). ECD was strongly expressed in normal gastric epithelium without exception; however, various staining patterns were observed in cancer tissues. The frequency of tumours with preserved ECD expression (Pre-type) and reduced ECD expression (Rd-type) was 42% and 58% respectively. Tumours with a high frequency of Rd-type expression particularly included: undifferentiated tumours (85%, 46/54), Borrmanns type 4 (90%, 9/10), tumours larger than 2.6 cm in diameter (65%, 53/81), tumours invading beyond the subserosa layer (78%, 46/59), and tumours with infiltrative growth (87%, 41/47). Furthermore, the frequency of Rd-type expression in cases with peritoneal dissemination (82%, 9/11) or lymph node metastasis (73%, 43/59) was significantly higher than that in cases without dissemination or metastasis. These results suggest that ECD might play a key role in the genesis of histological differentiation, and that the reduction of ECD expression may affect the mode of invasion and metastasis of human gastric cancer cells.


Japanese Journal of Cancer Research | 1992

p53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid Carcinomas

Tsutomu Nakamura; Ikuo Yana; Tetsuro Kobayashi; Eisei Shin; Katsu Karakawa; Shoichi Fujita; Akihiro Miya; Takesada Mori; Isamu Nishisho; Shin-ichiro Takai

Anaplastic carcinoma of the thyroid gland, which is one of the most aggressive, malignant tumors in humans, is considered to originate from preexisting differentiated thyroid cancer. To define the genetic alterations associated with such progression, we examined nine cases of anaplastic thyroid carcinoma for mutation in exons 4–9 of the p53 tumor suppressor gene. Preliminary screening for mutation by RNase protection analysis demonstrated that two out of nine anaplastic carcinomas contained sequence alterations in the p53 gene. Subsequent DNA sequencing identified the mutated nucleotides in these two cases; one was a nonsense mutation at codon 165, and the other was a single‐base deletion at codon 176 resulting in the creation of a stop codon downstream due to frameshift. The fact that no mutations were detected in coexisting foci of papillary carcinomas from the same patients shows that these mutations of the p53 gene occurred after development of papillary carcinomas. These results suggest that p53 gene mutation triggers the progression from differentiated into anaplastic carcinoma in the human thyroid gland.


Cytokine | 1992

Circulating interleukin 6 as a useful marker for predicting postoperative complications

Yoshio Oka; Atsuo Murata; Junichi Nishijima; Tadashi Yasuda; Nobuaki Hiraoka; Yoshitaka Ohmachi; Kazunori Kitagawa; Takushi Yasuda; Hitoshi Toda; Nobuo Tanaka; Takesada Mori

We examined postoperative serial changes in the levels of serum interleukin 6 (IL-6), serum acute phase reactants (APRs) and plasma neutrophil elastase (NE) in patients with various cancers and reviewed these changes in patients who did, and did not, show postoperative complications. Serum IL-6 level was elevated after surgery, peaking on the first postoperative day. Elevation of serum APRs and plasma NE levels also followed. There was a significant correlation between the serum peak level of IL-6 and those of APRs and NE (P less than 0.01). Moreover, there was a significant difference in the serum IL-6 level in patients with and without complications. The relationship between the serum IL-6 greater than 400 pg/ml and the incidence of postoperative complications was also marked. These results suggest that circulating IL-6 is a clinically useful marker for the earliest detection and prediction of postoperative complications.


Cancer Chemotherapy and Pharmacology | 1992

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study)

Saburo Kawai; Jun Okamura; Makoto Ogawa; Yasuo Ohashi; Masayoshi Tani; Jushiro Inoue; Yoshifumi Kawarada; Mitsuo Kusano; Yasuhiko Kubo; Chikazumi Kuroda; Yu Sakata; Yoshiyuki Shimamura; Kenji Jinno; Akira Takahashi; Kenichi Takayasu; Kazuo Tamura; Naofumi Nagasue; Yoshimi Nakanishi; Masaoki Makino; Manabu Masuzawa; Shuichi Mikuriya; Morito Monden; Yasuhiro Yumoto; Takesada Mori; Toshitsugu Oda

SummaryA randomized, controlled clinical trial comparing the use of lipiodol-transcatheter arterial embolization (L-TAE) in the presence versus the absence of Adriamycin (ADR) for the treatment of hepatocellular carcinoma was conducted from August 1988 through September 1989. In all, 125 Japanese hospitals participated in this study and 289 patients were entered in the trial. The patients were randomly allocated into group A (L-TAE) or group B (L-TAE+ADR) by telephone registration. There was no significant difference in background factors between group A and group B. Additional treatment, including repeated TAE or hepatic resection, was given to 189 patients. Among the four endpoints analyzed, the rate of tumor reduction and lipiodol accumulation in the tumor did not significantly differ between the two groups. The 3-year survival values for groups A and B were 33.6% and 34.9%, respectively; the difference was not significant. The serum alpha-fetoprotein level, however, decreased to a significantly greater extent in the group that received ADR than in the group that did not (P<0.05). This result suggests that ADR has some favorable additional effect in L-TAE for the treatment of hepatocellular carcinoma.


Cancer | 1993

Prognostic significance of transforming growth factor-α in human esophageal carcinoma : implication for the autocrine proliferation

Keisuke Iihara; Hitoshi Shiozaki; Hideaki Tahara; Kenji Kobayashi; Masatoshi Inoue; Shigeyuki Tamura; Mikiyo Miyata; Hiroshi Oka; Yuichiro Doki; Takesada Mori

Background. The authors recently used immunostaining to demonstrate that patients with epidermal growth factor receptor (EGFR) overexpression have poor survival after surgery. However, the clinical significance of transforming growth factor (TGF)‐α, one of the ligands of EGFR, has not been demonstrated in esophageal carcinoma.


Cancer | 1991

Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma

Hiroshi Yano; Hitoshi Shiozaki; Kenji Kobayashi; Tokiharu Yano; Hideaki Tahara; Shigeyuki Tamura; Takesada Mori

Epidermal growth factor receptor (EGF‐R) expression was studied immunohistologically in 38 patients with esophageal squamous cell carcinoma. The EGF‐R was faintly expressed in basal and parabasal layers of normal esophageal epithelia and in cancer nests of 20 patients; it was strongly expressed in all areas of dysplastic epithelia and in cancer nests of 18 patients. The patients with strongly expressed EGF‐R had lymph node metastases more frequently, and their prognosis was poorer than those with faintly expressed EGF‐R. The EGF‐R expression showed a mosaic pattern in 17 patients and a diffuse pattern in 21 patients. The patients with a mosaic pattern had lymph node metastases more frequently and a worse prognosis than those with a diffuse pattern. Expression of EGF‐R in metastatic lymph nodes was similar to that in strongly expressing areas of primary cancers with a mosaic pattern. Thus EGF‐R expression may be an important indicator for malignancies of esophageal squamous cell carcinomas because primary cancer cells with strongly expressed EGF‐R metastasize to lymph nodes more frequently.


Virchows Archiv | 1993

Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma

Kaoru Shimaya; Hitoshi Shiozaki; Masatoshi Inoue; Hideaki Tahara; Takushi Monden; Takashi Shimano; Takesada Mori

The tumour suppressor gene product p53 is believed to play an important role in the progression of human malignant tumours through mutation and over-expression. Using a microwave oven heating method, we have detected over-expression of p53 in buffered-formalin fixed, paraffin-embedded sections of oesophageal carcinomas immunohistochemically and examined the relationship between the p53 over-expression and postoperative survival. Employing a monoclonal antibody (pAb1801), nuclear p53 was detected in 56 of 105 (53%) tumour specimens. Homogeneous, heterogeneous, and focal immunostaining patterns were noted. No immunostaining was found in adjacent benign tissues. The results in buffered-formalin fixed sections were similar to those in the frozen sections. The cumulative survival rate of patients with p53 expression was significantly lower than that of the patients without expression (P<0.05), even though there were no significant differences between the clinicopathological features of the two groups. The results indicate that the nuclear accumulation of p53 might be an independent prognostic factor in patients with oesophageal squamous cell carcinomas.


Critical Care Medicine | 1995

Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model

Nobuo Tanaka; Atsuo Murata; Ken-ichi Uda; Hitoshi Toda; Takeshi Kato; Hirohito Hayashida; Nariaki Matsuura; Takesada Mori

OBJECTIVE Interleukin-1 (IL-1) is a mediator in some critical conditions such as septic shock and multiple organ failure. Acute pancreatitis is one of the noted causes of multiple organ failure but the mechanism by which local inflammation progresses to systemic disease is unknown. In this study, we used an IL-1 receptor antagonist (IL-1ra) to investigate whether multiple organ failure due to acute pancreatitis is mediated by IL-1, as in other causes such as severe infection, trauma, and major surgery. DESIGN Prospective, randomized, controlled trial. SETTING Research laboratory of a university medical school. SUBJECTS Specific pathogen-free male Wistar rats weighing 200 to 250 g. INTERVENTIONS Necrotizing pancreatitis was induced by retrograde injection of deoxycholate solution into the biliopancreatic duct. IL-1ra was injected intravenously at a dose of 10 mg/kg 15 mins before induction of acute pancreatitis and then infused continuously at a rate of 5 mg/kg/hr for the following 24 hrs. MEASUREMENTS AND MAIN RESULTS Although treatment with recombinant human IL-1ra did not affect the degree of local pancreatic insult, it significantly reduced mortality, improved urine output as an indicator of the state of shock, and ameliorated the accumulation of neutrophils into the lung in a rat experimental pancreatitis model. CONCLUSIONS We concluded that multiple organ failure in severe pancreatitis is mediated, at least in part, by IL-1 through the activation of neutrophils. Furthermore, we concluded that circulatory collapse may also be important in the mechanism of the lethal effect of pancreatitis.

Collaboration


Dive into the Takesada Mori's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mitsukazu Gotoh

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge